PROQURE-I:同期[177Lu]Lu-PSMA-617联合EBRT与ADT根治性治疗N1前列腺癌的I期研究
PURPOSE: Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates.…
要点
- 同期[177Lu]Lu-PSMA-617联合EBRT和ADT在初治N1M0前列腺癌中安全且耐受良好。
- 未观察到剂量限制性毒性,最大耐受剂量未达到。
- 报告的1-2级毒性均与EBRT相关。
核心结论
- 同期[177Lu]Lu-PSMA-617联合EBRT和ADT在初治N1M0前列腺癌患者中安全且耐受良好,临床疗效需在后续II期研究中评估。
主要发现
- 未观察到剂量限制性毒性,MTD未达到。
- 报告的1-2级毒性均与EBRT相关。
- 原发肿瘤中位吸收剂量在9 GBq组为0.71 Gy/GBq(IQR 0.5-2.9),7.4 GBq第1周期为0.91 Gy/GBq(IQR 0.6-1.0),第2周期为0.47 Gy/GBq(IQR 0.3-0.5)。
关键数值与推荐
- 剂量水平包括单周期(EBRT第2周给予3、6或9 GBq)或双周期(EBRT第2周和第4周给予2×7.4 GBq)。
- 剂量限制性毒性定义为CTCAE v5.0 ≥3级毒性。
- 肿瘤和器官剂量测定采用注射后4、24和168小时的SPECT/CT和平面显像进行。
临床怎么用
- 该方案为初治N1M0前列腺癌患者提供了一种安全且耐受良好的同期联合治疗选择,但疗效尚待II期研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT. METHODS: In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25-35 fractions) and 2-3 years ADT with concurrent [177Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection. RESULTS: Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1-2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5-2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3-0.5) at cycle 2. CONCLUSIONS: Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.
引用
- Zuur LG, Hoogenkamp DS, van der Sar ECA, et al. PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42201380. doi:10.1007/s00259-026-07956-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。